Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis:: Evaluation of a-ring-modified diphenyl ethers as high-affinity InhA inhibitors

被引:55
作者
Boyne, Melissa E.
Sullivan, Todd J.
amEnde, Christopher W.
Lu, Hao
Gruppo, Veronica
Heaslip, Darragh
Amin, Anita G.
Chatterjee, Delphi
Lenaerts, Anne
Tonge, Peter J. [1 ]
Slayden, Richard A.
机构
[1] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA
[2] Colorado State Univ, Dept Microbiol Immunol & Pahtol, Ft Collins, CO 80523 USA
[3] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA
关键词
D O I
10.1128/AAC.00383-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Structure-based design was used to develop a focused library of A-ring-modified diphenyl ether InbA inhibitors. From this library of analogs, two high-affinity alkyl-substituted diphenyl ethers, 6PP and 8PP, were selected for advanced study into their in vitro activity against Mycobacterium tuberculosis clinical isolates, their in vivo properties, and their signature response mode of action. 6PP and 8PP demonstrated enhanced activity against whole bacteria and showed activity in a rapid macrophage model of infection. In addition, transcriptional profiling revealed that the A-ring modifications of 6PP and 8PP increased the specificity of each analog for InhA. Both analogs had substantially longer half-lives in serum than did the parent compound, exhibited a fivefold reduction in cytotoxicity compared to the parent compound, and were well tolerated when administered orally at 300 mg/kg of body weight in animal models. Thus, the A-ring modifications increased the affinity and whole-cell specificity of the compounds for InhA and increased their bioavailability. The next step in optimization of the pharmacophore for preclinical evaluation is modification of the B ring to increase the bioavailability to that required for oral delivery.
引用
收藏
页码:3562 / 3567
页数:6
相关论文
共 20 条
[1]   INHA, A GENE ENCODING A TARGET FOR ISONIAZID AND ETHIONAMIDE IN MYCOBACTERIUM-TUBERCULOSIS [J].
BANERJEE, A ;
DUBNAU, E ;
QUEMARD, A ;
BALASUBRAMANIAN, V ;
UM, KS ;
WILSON, T ;
COLLINS, D ;
DELISLE, G ;
JACOBS, WR .
SCIENCE, 1994, 263 (5144) :227-230
[2]   Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs [J].
Barry, CE ;
Slayden, RA ;
Sampson, AE ;
Lee, RE .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (03) :221-231
[3]   Mycolic acids: Structure, biosynthesis and physiological functions [J].
Barry, CE ;
Lee, RE ;
Mdluli, K ;
Sampson, AE ;
Schroeder, BG ;
Slayden, RA ;
Yuan, Y .
PROGRESS IN LIPID RESEARCH, 1998, 37 (2-3) :143-179
[4]   Mechanisms of isoniazid resistance in Mycobacterium tuberculosis:: Enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates [J].
Basso, LA ;
Zheng, RJ ;
Musser, JM ;
Jacobs, WR ;
Blanchard, JS .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) :769-775
[5]   Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis [J].
Belisle, JT ;
Vissa, VD ;
Sievert, T ;
Takayama, K ;
Brennan, PJ ;
Besra, GS .
SCIENCE, 1997, 276 (5317) :1420-1422
[6]   The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism -: Novel insights into drug mechanisms of action [J].
Boshoff, HIM ;
Myers, TG ;
Copp, BR ;
McNeil, MR ;
Wilson, MA ;
Barry, CE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (38) :40174-40184
[7]   The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol [J].
Colangeli, R ;
Helb, D ;
Sridharan, S ;
Sun, JC ;
Varma-Basil, M ;
Hazbón, MH ;
Harbacheuski, R ;
Megjugorac, NJ ;
Jacobs, WR ;
Holzenburg, A ;
Sacchettini, JC ;
Alland, D .
MOLECULAR MICROBIOLOGY, 2005, 55 (06) :1829-1840
[8]   Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis [J].
Gruppo, V ;
Johnson, CM ;
Marietta, KS ;
Scherman, H ;
Zink, EE ;
Crick, DC ;
Adams, LB ;
Orme, IM ;
Lenaerts, AJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1245-1250
[9]   MISSENSE MUTATIONS IN THE CATALASE-PEROXIDASE GENE, KATG, ARE ASSOCIATED WITH ISONIAZID RESISTANCE IN MYCOBACTERIUM-TUBERCULOSIS [J].
HEYM, B ;
ALZARI, PM ;
HONORE, N ;
COLE, ST .
MOLECULAR MICROBIOLOGY, 1995, 15 (02) :235-245
[10]   Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis [J].
Kremer, L ;
Douglas, JD ;
Baulard, AR ;
Morehouse, C ;
Guy, MR ;
Alland, D ;
Dover, LG ;
Lakey, JH ;
Jacobs, WR ;
Brennan, PJ ;
Minnikin, DE ;
Besra, GS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) :16857-16864